Diabetes Research and Clinical Practice
Volume 76, Issue 2 , Pages 229-235 , May 2007

Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan

  • Ryuzo Kawamori

      Affiliations

    • Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, 2-1-1 Hongo Bunkyo-ku, Tokyo, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 3 5802 1578; fax: +81 3 3813 5996.
    • ,
  • Takashi Kadowaki

      Affiliations

    • Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • ,
  • Morikazu Onji

      Affiliations

    • Third Department of Internal Medicine, Ehime University School of Medicine, Toon, Japan
    • ,
  • Yutaka Seino

      Affiliations

    • Kansai Electric Power Hospital, Osaka, Japan
    • ,
  • Yasuo Akanuma

      Affiliations

    • Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan
    • ,
  • on behalf of the PRACTICAL Study Group

      Affiliations

    • The PRACTICAL (PRospective ACTos practICAL experience) Study Group is composed of physicians at 4093 institutions in all 47 prefectures of Japan.

Received 28 March 2006 ,Revised 9 June 2006 ,Accepted 30 August 2006.

References 

  1. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diab. Care. 2005;28:1547–1554
  2. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diab. Care. 2004;27:41–46
  3. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–1289
  4. Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y. Interim Analysis on PRACTICAL (PRospective ACTos practICAL experience) Study: Efficacy and Safety in Over 20,000 Japanese Type 2 Diabetes Patients. In: 64th American Diabetes Association. June, Orland, Florida. 2004;4–8
  5. Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y. PRACTICAL (PRospective ACTos practICAL experience) Study: Updated Efficacy and Safety in 23,000 Japanese Type 2 Diabetes Patients. In: 65th American Diabetes Association. June, San Diego, California. 2005;10–14
  6. Robert TO. In:  Karl EP editors. Biopharmaceutical Statistics for Drug Development. New York, US: Marcel Dekker; 1988;p. 543–604
  7. Watkins PB, Whitcomb Randall W. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 1998;338:916–917
  8. Takeda Pharmaceuticals America, Inc., Actos (Pioglitazone Hydrochloride) Tablets, Prescribing Information, Lincolnshire, US, 2000.
  9. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am. J. Gastroenterol. 2003;98:175–179
  10. Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diab. Med. 2005;22:973–979
  11. Belcher G, Lambert C, Edwards G, Urquhart R, Matthews DR. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diab. Res. Clin. Pract. 2005;70:53–62
  12. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541–3546
  13. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52:1364–1370
  14. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188–196
  15. Charbonnel B, Matthews DR, Schernthaner G, Hanefeld M on behalf of the QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diab. Med. 2004;22:399–405
  16. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P on behalf of the QUARTET Study Group. Efficacy and safety of pioglitazone versus metformin: a double-blind, randomized trial. J. Clin. Endcr. Metab. 2004;89:6068–6076
  17. Takeda Pharmaceuticals, Co., Actos (Pioglitazone Hydrochloride) Tablets, Prescribing Information, Osaka, Japan, 2006.
  18. Data from the Annual Japanese Health, Labour and Welfare Statistics (Monograph), Health and Statistics Association, Ministry of Health, Labour and Welfare, Tokyo, Japan, 2002.
  19. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984;26:44–49
  20. Sone H, Mizuno S, Fujii H, Yoshimura Y, Yamasaki Y, Ishibashi S, et al. Japan Diabetes Complications Study: Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diab. Care. 2005;28:1463–1471
  21. Fukushima M, Usami M, Ikeda M, Nakai Y, Taniguchi A, Seino Y, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism. 2004;53:831–835
  22. Torrens JI, Skurnick J, Davidow AL, Korenman SG, Santoro N, Soto-Greene M, et al. Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN). Diab. Care. 2004;27:354–361
  23. Kanauchi M, Nakajima M, Saito Y, Kanauchi K. Pancreatic beta-cell function and insulin sensitivity in Japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. Metabolism. 2003;52:476–481

PII: S0168-8227(06)00399-8

doi: 10.1016/j.diabres.2006.08.017

Diabetes Research and Clinical Practice
Volume 76, Issue 2 , Pages 229-235 , May 2007

Article Tools

* Image Usage & Resolution